Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10

Literature DB >> 33229356

Wei Liu¹, Pengxiang Zhou¹, Ken Chen¹, Zhikang Ye¹, Fang Liu¹, Xiaotong Li¹, Na He¹, Ziyang Wu¹, Qi Zhang¹, Xuepeng Gong¹, Qiyu Tang¹, Xin Du¹, Yingqiu Ying¹, Xiaohan Xu¹, Yahui Zhang¹, Jinyu Liu¹, Yun Li¹, Ning Shen¹, Rachel J Couban¹, Quazi I Ibrahim¹, Gordon Guyatt¹, Suodi Zhai².

Abstract

Entities: Chemical

Mesh：

Substances：
Antiviral Agents

Year: 2020 PMID： 33229356 PMCID： PMC7721259 DOI： 10.1503/cmaj.200647-f

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

34 in total

1. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays.

Authors: Brit J Hart; Julie Dyall; Elena Postnikova; Huanying Zhou; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Matthew B Frieman; Michael R Holbrook; Peter B Jahrling; Lisa Hensley
Journal: J Gen Virol Date: 2013-12-09 Impact factor: 3.891

2. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures].

Authors: R A Khamitov; S Ia Loginova; V N Shchukina; S V Borisevich; V A Maksimov; A M Shuster
Journal: Vopr Virusol Date: 2008 Jul-Aug

3. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.

Authors: Anita Patel; Daniel B Jernigan
Journal: MMWR Morb Mortal Wkly Rep Date: 2020-02-07 Impact factor: 17.586

Review 4. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.

Authors: Hisham Momattin; Khurram Mohammed; Alimuddin Zumla; Ziad A Memish; Jaffar A Al-Tawfiq
Journal: Int J Infect Dis Date: 2013-08-29 Impact factor: 3.623

5. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Authors: Yeming Wang; Dingyu Zhang; Guanhua Du; Ronghui Du; Jianping Zhao; Yang Jin; Shouzhi Fu; Ling Gao; Zhenshun Cheng; Qiaofa Lu; Yi Hu; Guangwei Luo; Ke Wang; Yang Lu; Huadong Li; Shuzhen Wang; Shunan Ruan; Chengqing Yang; Chunlin Mei; Yi Wang; Dan Ding; Feng Wu; Xin Tang; Xianzhi Ye; Yingchun Ye; Bing Liu; Jie Yang; Wen Yin; Aili Wang; Guohui Fan; Fei Zhou; Zhibo Liu; Xiaoying Gu; Jiuyang Xu; Lianhan Shang; Yi Zhang; Lianjun Cao; Tingting Guo; Yan Wan; Hong Qin; Yushen Jiang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Bin Cao; Chen Wang
Journal: Lancet Date: 2020-04-29 Impact factor: 79.321

Review 6. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis.

Authors: Mostafa Ebraheem Morra; Le Van Thanh; Mohamed Gomaa Kamel; Ahmed Abdelmotaleb Ghazy; Ahmed M A Altibi; Lu Minh Dat; Tran Ngoc Xuan Thy; Nguyen Lam Vuong; Mostafa Reda Mostafa; Sarah Ibrahim Ahmed; Sahar Samy Elabd; Samreen Fathima; Tran Le Huy Vu; Ali S Omrani; Ziad A Memish; Kenji Hirayama; Nguyen Tien Huy
Journal: Rev Med Virol Date: 2018-04-17 Impact factor: 6.989

7. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.

Authors:
Journal: Nat Microbiol Date: 2020-03-02 Impact factor: 17.745

8. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.

Authors: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Journal: Med (N Y) Date: 2020-05-19

1. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays.

2. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures].

3. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.

Review 4. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.

5. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Review 6. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis.

7. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.

8. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.

9. Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome.

10. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.

1. Provider attitudes and satisfaction with rapid preoperative point-of-care COVID-19 testing using ID NOW™.

Review 2. End-of-life care in patients with a highly transmissible respiratory virus: implications for COVID-19.